Mumbai, Feb. 7 -- The said drug is equivalent to BromSite Ophthalmic Solution of Sun Pharmaceutical Industries. It will manufactured at Lupin's Pithampur facility in India.

Bromfenac Ophthalmic Solution, 0.075% is indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.

As per IQVIA MAT December 2023, Bromfenac Ophthalmic Solution 0.075% had estimated annual sales of $15 million in the US.

Meanwhile, the company's board will meet today, 7 February 2024 to consider and take on record the unaudited standalone and consolidated financial results of the company for the quarter and nine-months ended December 31, 2023.

Mumbai-based Lupin is an innovation-led transnationa...